CRSP FY2024 EPS Estimate Cut by Brookline Capital Management

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities researchers at Brookline Capital Management reduced their FY2024 EPS estimates for CRISPR Therapeutics in a research report issued on Tuesday, November 5th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($5.18) per share for the year, down from their prior forecast of ($4.88). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.57) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($1.36) EPS, FY2025 earnings at ($5.76) EPS, FY2026 earnings at $8.07 EPS, FY2027 earnings at $11.96 EPS and FY2028 earnings at $26.00 EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.41. The business had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same quarter in the previous year, the firm posted ($1.41) EPS.

A number of other brokerages have also recently commented on CRSP. Chardan Capital lowered their price target on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Thursday. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Royal Bank of Canada restated a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday. Finally, Rodman & Renshaw assumed coverage on CRISPR Therapeutics in a report on Friday, August 2nd. They set a “buy” rating and a $90.00 target price on the stock. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $74.94.

CRISPR Therapeutics Trading Up 2.3 %

NASDAQ CRSP opened at $51.88 on Friday. CRISPR Therapeutics has a 12 month low of $43.42 and a 12 month high of $91.10. The stock has a 50-day simple moving average of $47.38 and a 200 day simple moving average of $52.24. The company has a market capitalization of $4.41 billion, a PE ratio of -16.06 and a beta of 1.67.

Insider Activity

In related news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now directly owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CRSP. Global Trust Asset Management LLC lifted its stake in CRISPR Therapeutics by 150.0% in the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after purchasing an additional 300 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after acquiring an additional 276 shares during the last quarter. GPS Wealth Strategies Group LLC raised its stake in CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after acquiring an additional 307 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in CRISPR Therapeutics during the 2nd quarter valued at $35,000. Finally, Denver PWM LLC acquired a new position in shares of CRISPR Therapeutics in the second quarter valued at $45,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.